Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As society battles with an obesity epidemic, new research from the Edwards group shows how increased body fat contributes to cancer establishment and progression.

Mouse bone marrow adipocytes stained with bodipy, a fluorescent dye that is taken up by lipid droplets.

Multiple myeloma is an incurable haematological cancer associated with the expansion of abnormal plasma cells within the bone marrow and the development of destructive bone disease. In the last couple of decades, bone marrow fat cells (adipocytes) have emerged as having an important role in bone physiology in health and disease. Research from Prof. Claire Edwards’ team at the Botnar Research Centre, and published in the Journal of Bone and Mineral Research, identifies a new mechanism by which myeloma cells alter the bone microenvironment to support disease progression. 

“We have previously shown the importance of diet-induced obesity and low levels of adiponectin, a tumour-suppressive adipokine, in the development of myeloma’ said Claire Edwards. “In this study we show how myeloma cells alter bone marrow adipocytes to regulate production of adiponectin”.  The first author of the study, Dr. Emma Morris, said “We found that in early-stage myeloma the amount of fat in the bones increased and that myeloma cells utilised the molecules the fat cells produce for growth and survival, with TNF-alpha found to be important in the downregulation of adiponectin”.

Myeloma has been described as an obesity-associated cancer with a 20% increased risk of disease progression in obese individuals. As society battles with an obesity epidemic, efforts to understand the contribution of increased body fat to cancer establishment and progression are becoming increasingly important, with growing evidence for a key role of bone marrow adipose tissue in cancers that arise in or metastasise to bone. 

Similar stories

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.